about
Agent-Based Modeling in Systems PharmacologyBasic Concepts in Population Modeling, Simulation, and Model-Based Drug DevelopmentClinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis.Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review.An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria.Creating groups with similar expected behavioural response in randomized controlled trials: a fuzzy cognitive map approach.Modelling approaches to dose estimation in childrenPopulation pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.Generating Virtual Patients by Multivariate and Discrete Re-Sampling TechniquesStatistical methods for HIV dynamic studies in AIDS clinical trials.Evidence of effectiveness: how much can we extrapolate from existing studies?Pharmacogenetics approach to therapeutics.Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and DocumentationPharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavirPharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.Role of modelling and simulation: a European regulatory perspective.Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)Optimizing drug development in oncology by clinical trial simulation: Why and how?Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution.Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century.Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.
P2860
Q28602444-56CC2FB2-6BCD-4DB2-8B73-5D502B5A6B52Q29013931-2ED8560C-8818-40FF-B6C3-E79A3773CC61Q30542069-CDB4B60A-8D46-49EA-BD2A-5CCD98ADCA1BQ33373185-F1218754-B8DF-4DDC-991B-E3DD80935105Q34526733-CCD02CD3-152E-493F-BCEB-40B67BE9786CQ34937857-90E2AAD4-6A2B-43EF-9E8A-CC5421626B43Q35827045-3D922F68-B616-41F7-8409-6C8B41D2A1D2Q35928858-A5A8CFBA-6113-4384-916C-6AE0A28E892BQ36080108-E6F4C6E6-52A0-46DA-9FA3-6B1207559183Q36088015-EB2ACF78-3A43-4FC5-A8EB-EDDB03A6C683Q36341627-600DE125-E8A6-4A35-B63E-A21417EBC710Q36478845-76A9AEC5-9D7D-4BE5-9341-A91F2F0A8AAFQ36734132-94328B2F-8345-42E6-9476-6EA158E52AD9Q37032799-8C2DB982-A0B1-47C5-810B-822801178DDEQ37274688-F458D899-C5F1-4A8B-975F-4B5E86268185Q37293688-E73BCECF-112F-4C02-8312-574CAB2C5501Q37799461-62241CA4-EC09-4B39-A079-610A371E8FFFQ37976876-5A244C45-B787-42F1-9D48-DF7BB666A0A3Q38672541-59F10948-A1B6-4591-9C52-5702FFF2085CQ38675644-F269B668-852A-43D5-AB88-8D6E31127C55Q39715580-A76F1F45-7727-4FD7-B4B4-9F969C4BB844Q40598093-DC5FC7C7-DF0E-4644-9A83-09C7475F0819Q40749507-CC2F0FF5-872F-408F-A342-E44151D5C921Q43985737-87ED0B76-15FA-4B3D-9FB7-F3889A0138F9Q47103417-D89C3625-0972-4E74-A746-3D661D56D1D8
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Clinical trial simulation in drug development.
@ast
Clinical trial simulation in drug development.
@en
type
label
Clinical trial simulation in drug development.
@ast
Clinical trial simulation in drug development.
@en
prefLabel
Clinical trial simulation in drug development.
@ast
Clinical trial simulation in drug development.
@en
P356
P1476
Clinical trial simulation in drug development.
@en
P2093
P304
P356
10.1023/A:1007548719885
P577
2000-03-01T00:00:00Z